Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Recursion Pharmaceuticals, Inc. RXRX

Healthcare  —  Biotechnology
3.74 (0.15) (3.86%) as of 25 Sep
Market cap
$2.1B
P/E
0.0×
Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Recursion Pharmaceuticals, Inc. (RXRX) Business Profile

Updated before January 2025

Company Overview

Recursion Pharmaceuticals, Inc. (RXRX) is a biotechnology company that leverages advanced computational techniques and machine learning to accelerate drug discovery and development. Founded in 2013 by Chris Gibson, Ph.D., and his team in Salt Lake City, Utah, Recursion aims to revolutionize the pharmaceutical industry by combining biology, chemistry, and artificial intelligence (AI). The company’s mission is to decode biology to radically improve lives.

Chris Gibson, who serves as the CEO, has been instrumental in driving the company’s vision. Other key members of the leadership team include Tina Larson (COO), Ben Mabey (CTO), and Ron Alfa (SVP of Translational Discovery). The company went public in April 2021 and trades on the NASDAQ under the ticker symbol RXRX.

Core Business Segments

Recursion Pharmaceuticals operates at the intersection of technology and life sciences. Its core business segments include:

Drug Discovery and Development

Recursion’s primary focus is on drug discovery and development. The company uses its proprietary Recursion Operating System (Recursion OS), a platform that integrates high-throughput biology, advanced imaging, and machine learning to identify potential drug candidates. This platform enables Recursion to analyze millions of biological experiments in parallel, significantly reducing the time and cost associated with traditional drug discovery methods.

Key therapeutic areas include:

  • Rare Genetic Diseases: Recursion has a strong pipeline of drug candidates targeting rare genetic disorders, including conditions like neurofibromatosis type 2 (NF2) and familial adenomatous polyposis (FAP).
  • Oncology: The company is actively exploring treatments for various cancers, leveraging its AI-driven platform to identify novel therapeutic targets.
  • Fibrosis: Recursion is developing treatments for fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and other related conditions.

Partnerships and Collaborations

Recursion collaborates with leading pharmaceutical companies to expand its drug discovery capabilities. Notable partnerships include collaborations with Bayer and Roche, focusing on areas such as oncology and neuroscience. These partnerships not only provide additional revenue streams but also validate Recursion’s technology-driven approach.

Data and Technology Licensing

In addition to drug development, Recursion generates revenue by licensing its proprietary datasets and machine learning algorithms to other biotech and pharmaceutical companies. This segment underscores the company’s dual identity as both a biotech and a tech company.

Business Model

Recursion’s business model is built on the integration of cutting-edge technology and life sciences. The company generates revenue through:

  1. Drug Development: Recursion advances its own pipeline of drug candidates, aiming to bring them to market or license them to larger pharmaceutical companies.
  2. Collaborations and Partnerships: By partnering with established pharmaceutical companies, Recursion gains access to additional resources and expertise while sharing the financial risks and rewards of drug development.
  3. Technology Licensing: The company monetizes its proprietary datasets and AI algorithms by licensing them to other organizations.

This diversified approach allows Recursion to mitigate risks and capitalize on multiple revenue streams.

Strategic Direction

Recursion Pharmaceuticals has a clear strategic vision for the future:

  1. Pipeline Expansion: The company plans to expand its pipeline of drug candidates, focusing on both rare diseases and more common conditions.
  2. Global Expansion: Recursion aims to establish a stronger presence in international markets, leveraging its partnerships with global pharmaceutical companies.
  3. Sustainability Goals: The company is committed to sustainability, both in terms of its environmental impact and its long-term business practices.
  4. Technological Advancements: Recursion continues to invest in its Recursion OS platform, enhancing its capabilities to analyze complex biological data and accelerate drug discovery.

Competitive Landscape

Recursion operates in a highly competitive industry, facing competition from both traditional pharmaceutical companies and tech-driven biotech firms. Key competitors include:

  • Exscientia: A UK-based company that uses AI for drug discovery.
  • Insitro: A biotech company combining machine learning and biology to develop new therapies.
  • Atomwise: Focused on AI-driven drug discovery, particularly in small molecule therapeutics.
  • Traditional Pharma Companies: Large pharmaceutical companies like Pfizer and Novartis, which have their own drug discovery programs.

Recursion differentiates itself through its proprietary technology platform and its focus on integrating biology, chemistry, and AI.

Risk Factors

Like any company in the biotech sector, Recursion faces several risks:

  1. Regulatory Challenges: The drug development process is heavily regulated, and delays or failures in clinical trials could impact the company’s financial performance.
  2. Market Dependence: Recursion relies on the success of its drug candidates and partnerships for revenue generation.
  3. Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply chain, particularly for specialized equipment and materials.
  4. Competition: The biotech industry is highly competitive, and advancements by competitors could impact Recursion’s market position.

Recent Developments

In recent years, Recursion has made significant strides:

  • Partnership with Roche: In 2021, Recursion announced a multi-year collaboration with Roche to develop new therapies for neuroscience and oncology.
  • IPO: The company’s successful IPO in April 2021 raised significant capital to fund its research and development efforts.
  • Technological Innovations: Recursion continues to enhance its Recursion OS platform, incorporating new machine learning algorithms and expanding its dataset.

Investment Considerations

Strengths

  • Innovative Technology: Recursion’s AI-driven platform sets it apart from traditional biotech companies.
  • Strong Pipeline: The company has a robust pipeline of drug candidates targeting high-value therapeutic areas.
  • Strategic Partnerships: Collaborations with industry leaders like Bayer and Roche validate Recursion’s approach and provide additional resources.

Risks

  • High R&D Costs: Drug development is expensive, and there is no guarantee of success.
  • Regulatory Uncertainty: The approval process for new drugs is complex and time-consuming.
  • Market Volatility: As a publicly traded company, Recursion’s stock price is subject to market fluctuations.

Conclusion

Recursion Pharmaceuticals is at the forefront of a new era in drug discovery, leveraging AI and machine learning to accelerate the development of life-saving therapies. While the company faces significant challenges, its innovative approach, strong leadership, and strategic partnerships position it for long-term success. Investors should weigh the potential rewards against the inherent risks of investing in a biotech company.